Injectable / Weight Loss & GLP-1

GLP-3 Reta

Triple Agonist GIP/GLP-1/Glucagon

GLP-3 Reta, injectable, front

From $159 USD · In stock · 11mg / 2mL vial

  • 11mg (11mg / 2mL vial): $159
  • 22mg (22mg / 2× 2mL vial): $279
  • 33mg (33mg / 3× 2mL vial): $359

Next-generation triple-receptor agonist activating GIP, GLP-1, and glucagon pathways. The most efficacious metabolic peptide in clinical development.

Product information

Retatrutide (LY3437943) is a first-in-class triple agonist activating GIP, GLP-1, and glucagon receptors simultaneously. By engaging all three incretin-related pathways, retatrutide produces the most significant weight loss outcomes observed in any GLP-1-class therapy to date.

Phase 2 clinical trials demonstrated up to 24.2% body weight reduction at 48 weeks, exceeding both semaglutide and tirzepatide. The glucagon component adds direct hepatic and adipose effects, accelerating lipolysis alongside appetite suppression. Pharmaceutical-grade, HPLC-verified, 99.5%+ purity.

Benefits

  • Triple receptor agonism (GIP/GLP-1/Glucagon)
  • Most significant weight loss outcomes to date
  • Direct lipolytic glucagon activity
  • Superior to tirzepatide in head-to-head

Specifications

Fill / pack
11mg / 2mL vial
Format
Injectable
Serving
2-12mg weekly
Servings per container
5-12 weeks supply
Listed purity
99.75%
Molecular weight / composition
4731.36 Da
Storage
Refrigerate 2-8°C

View product certificate of analysis

For laboratory and research use only. Not for human consumption.

Browse all peptide bioregulators or the Weight Loss & GLP-1 collection. All formulations.